Faga Daniel 4
4 · ANAPTYSBIO, INC · Filed Apr 22, 2026
Research Summary
AI-generated summary of this filing
AnaptysBio (ANAB) CEO Daniel Faga Receives Adjusted Options
What Happened On April 20, 2026, Daniel Faga (President, CEO and Director of AnaptysBio) had multiple derivative option positions adjusted: the filing shows paired dispositions to the issuer and re-grants (codes D and A) for a total of 1,035,941 optioned shares (each line at $0.00). These entries reflect an administrative adjustment tied to a corporate separation/spin-off, not an open‑market sale or purchase — no cash was received or paid.
Key Details
- Transaction date: April 20, 2026; Form 4 filed April 22, 2026 (timely within the normal 2‑business‑day window).
- Actions reported: multiple dispositions to issuer (D) and corresponding grants/awards (A) — all at $0.00 per share (derivative adjustments).
- Total options affected (sum of reported lines): 1,035,941 optioned shares cancelled and reissued in equal amounts.
- Shares owned after transaction: not disclosed in the supplied filing excerpt.
- Relevant footnote F1: adjustments were made pursuant to a pro rata distribution under the Separation and Distribution Agreement with First Tracks — each outstanding option was adjusted into an option for First Tracks shares and an option for AnaptysBio shares, resulting in the reported acquisitions of AnaptysBio options.
- Vesting notes (F2–F6): one option is fully vested (F2); others have time‑based vesting schedules (25% at initial date then monthly 1/48th vesting) with various start dates through 2027 (see F3–F6).
Context These are derivative/option adjustments tied to a corporate separation rather than routine insider buying or selling. Because the transactions are technical re‑allocations (no cash exchange, no open‑market trades), they do not directly signal insider buying or selling sentiment. Vesting schedules noted in the filing indicate some options are already vested while others vest over time, which affects when the holder could potentially convert options to shares.
Insider Transaction Report
- Disposition to Issuer
Employee Stock Option (right to buy)
[F1][F2]2026-04-20−11,000→ 16,510 totalExercise: $31.12Exp: 2031-11-25→ Common Stock (16,510 underlying) - Award
Employee Stock Option (right to buy)
[F1][F2]2026-04-20+11,000→ 11,000 totalExercise: $22.80Exp: 2031-11-25→ Common Stock (11,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
[F1][F2]2026-04-20−2,321→ 2,321 totalExercise: $31.12Exp: 2031-11-25→ Common Stock (2,321 underlying) - Award
Employee Stock Option (right to buy)
[F1][F2]2026-04-20+2,321→ 2,321 totalExercise: $22.80Exp: 2031-11-25→ Common Stock (2,321 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
[F1][F2]2026-04-20−9,200→ 9,200 totalExercise: $30.44Exp: 2032-02-09→ Common Stock (9,200 underlying) - Award
Employee Stock Option (right to buy)
[F1][F2]2026-04-20+9,200→ 9,200 totalExercise: $22.31Exp: 2032-02-09→ Common Stock (9,200 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
[F1][F3]2026-04-20−194,900→ 194,900 totalExercise: $23.23Exp: 2033-01-05→ Common Stock (194,900 underlying) - Award
Employee Stock Option (right to buy)
[F1][F3]2026-04-20+194,900→ 194,900 totalExercise: $17.02Exp: 2033-01-05→ Common Stock (194,900 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
[F1][F4]2026-04-20−379,620→ 379,620 totalExercise: $21.19Exp: 2034-01-02→ Common Stock (379,620 underlying) - Award
Employee Stock Option (right to buy)
[F1][F4]2026-04-20+379,620→ 379,620 totalExercise: $15.53Exp: 2034-01-02→ Common Stock (379,620 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
[F1][F5]2026-04-20−305,500→ 305,500 totalExercise: $14.83Exp: 2035-01-06→ Common Stock (305,500 underlying) - Award
Employee Stock Option (right to buy)
[F1][F5]2026-04-20+305,500→ 305,500 totalExercise: $10.87Exp: 2035-01-06→ Common Stock (305,500 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
[F1][F6]2026-04-20−133,400→ 133,400 totalExercise: $43.91Exp: 2036-01-06→ Common Stock (133,400 underlying) - Award
Employee Stock Option (right to buy)
[F1][F6]2026-04-20+133,400→ 133,400 totalExercise: $32.17Exp: 2036-01-06→ Common Stock (133,400 underlying)
Footnotes (6)
- [F1]Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
- [F2]The stock option is fully vested and exercisable.
- [F3]The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F4]The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F5]The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F6]The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.